A phase I study of dovitinib (TKI258) in Japanese patients with advanced solid tumors

被引：0
|
作者：
Takiuchi, Hiroya
Gotoh, Masahiro
Yoshida, Motoki
Kii, Takayuki
Yamashita, Keishi
Sunakawa, Yu
Kaneta, Toshikado
Robson, Matthew
Kakizume, Tomoyuki
Sasaki, Yasutsuna
机构：
[1] Osaka Med Coll, Osaka, Japan
[2] Osaka Med Coll Hosp, Osaka, Japan
[3] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[4] Novartis Pharma KK, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3088
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors
    Sharma, Sunil
    Britten, Carolyn D.
    Mortimer, Joanne
    Kulkarni, Swarupa
    Quinlan, Michelle
    Liu, Angela
    Scott, Jeffrey W.
    George, Daniel
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 867 - 874
  • [2] The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors
    Sunil Sharma
    Carolyn D. Britten
    Joanne Mortimer
    Swarupa Kulkarni
    Michelle Quinlan
    Angela Liu
    Jeffrey W. Scott
    Daniel George
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 867 - 874
  • [3] A phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma
    Kim, K. B.
    Saro, J.
    Moschos, S. S.
    Hwu, P.
    Tarhini, A. A.
    Hwu, W.
    Jones, G.
    Wang, Y.
    Rupani, H.
    Kirkwood, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase I trial of dovitinib (TKI258) in recurrent glioblastoma
    Niklas Schäfer
    Gerrit H. Gielen
    Sied Kebir
    Anja Wieland
    Andreas Till
    Frederic Mack
    Christina Schaub
    Theophilos Tzaridis
    Roman Reinartz
    Michael Niessen
    Rolf Fimmers
    Matthias Simon
    Christoph Coch
    Christine Fuhrmann
    Ulrich Herrlinger
    Björn Scheffler
    Martin Glas
    Journal of Cancer Research and Clinical Oncology, 2016, 142 : 1581 - 1589
  • [5] Phase 1 study assessing dovitinib (TKI258) on the pharmacokinetics of caffeine, diclofenac, omeprazole, and midazolam in patients with advanced solid tumors.
    Wang, Ding
    Perez, Raymond P.
    Moss, Rebecca Anne
    Yang, Shu
    Cui, Xiaoming
    Quadrigil, Massimillano
    Scott, Jeffrey W.
    Bralteh, Fadi S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Phase I trial of dovitinib (TKI258) in recurrent glioblastoma
    Schaefer, Niklas
    Gielen, Gerrit H.
    Kebir, Sied
    Wieland, Anja
    Till, Andreas
    Mack, Frederic
    Schaub, Christina
    Tzaridis, Theophilos
    Reinartz, Roman
    Niessen, Michael
    Fimmers, Rolf
    Simon, Matthias
    Coch, Christoph
    Fuhrmann, Christine
    Herrlinger, Ulrich
    Scheffler, Bjoern
    Glas, Martin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (07) : 1581 - 1589
  • [7] Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors
    John Sarantopoulos
    Sanjay Goel
    Vincent Chung
    Pamela Munster
    Shubham Pant
    Manish R. Patel
    Jeffrey Infante
    Hussein Tawbi
    Carlos Becerra
    Justine Bruce
    Fairooz Kabbinavar
    A. Craig Lockhart
    Eugene Tan
    Shu Yang
    Gary Carlson
    Jeffrey W. Scott
    Sunil Sharma
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 921 - 927
  • [8] Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors
    Sarantopoulos, John
    Goel, Sanjay
    Chung, Vincent
    Munster, Pamela
    Pant, Shubham
    Patel, Manish R.
    Infante, Jeffrey
    Tawbi, Hussein
    Becerra, Carlos
    Bruce, Justine
    Kabbinavar, Fairooz
    Lockhart, A. Craig
    Tan, Eugene
    Yang, Shu
    Carlson, Gary
    Scott, Jeffrey W.
    Sharma, Sunil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (05) : 921 - 927
  • [9] Relative bioavailability of dovitinib (TKI258) formulations
    Garonzik, Samira
    Nedelman, Jerry
    Scott, Jeffrey
    Cramer, Jeffrey
    Tan, Eugene
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Phase II study of dovitinib (TKI258) in patients with progressive metastatic adenoid cystic carcinoma
    Dillon, Patrick Michael
    Moskaluk, Chris
    Fracasso, Paula M.
    Petroni, Gina R.
    Thomas, Christopher Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345